取得学位 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

所属学会・委員会 【 表示 ／ 非表示 】

所属学会・委員会 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Prognostic Factors of Cervical Adenocarcinoma With Positive Pelvic Lymph Node Metastases Without Preoperative Lymph Node Enlargement Treated With Radical Hysterectomy.

  Watanabe T, Tamashiro N, Shimoji Y, Arakaki Y, Taira Y, Nakamoto T, Kudaka W, Aoki Y

  Cancer diagnosis & prognosis   3 ( 1 ) 96 - 101   2023年01月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Low-set umbilicus in a pregnant woman with bladder pseudoexstrophy: A case report.

  Taira Y, Yara N, Kinjo Y, Kinjo T, Mekaru K, Aoki Y

  Case reports in women's health ( Case Reports in Women's Health )  36   e00467   2022年10月 [ 査読有り ]

  掲載種別: 研究論文（その他学術会議資料等）

  　概要を見る

  Bladder pseudoexstrophy is a rare form of bladder exstrophy. Bladder exstrophy occurs in 1 in every 30,000 to 50,000 live births. Because bladder pseudoexstrophy is asymptomatic, it may be undiagnosed even in adulthood. A 31-year-old woman with uterus bicornis unicollis and a low-set umbilicus underwent emergency cesarean delivery during the 37th week of pregnancy for chorioamnionitis. Perioperatively, asymptomatic anatomical abnormalities were identified, which included separated rectus abdominis muscles and diastasis of the symphysis pubis. The urinary tract was normal. The patient was diagnosed with bladder pseudoexstrophy. A low-set umbilicus may be a potential marker for the diagnosis of bladder pseudoextrophy.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.

  Ooyama T, Shimoji Y, Nakasone T, Arakaki Y, Taira Y, Nakamoto T, Kudaka W, Aoki Y

  Anticancer research ( Anticancer Research )  42 ( 6 ) 3017 - 3022   2022年06月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  BACKGROUND/AIM: Ovarian cancer is a disease with significant impact, because more than half of cases exhibit recurrence despite platinum therapy. The choice of drug for cases of recurrence remains controversial, but the current option is pegylated liposomal doxorubicin (PLD). PATIENTS AND METHODS: We retrospectively reviewed the use of PLD in patients with ovarian cancer refractory or resistant to platinum-based therapy at our Department. We also examined efficacy, predictive indices of efficacy, and adverse events as well. RESULTS: In this study of PLD monotherapy for 60 platinum-refractory/resistant recurrent ovarian cancers, there was a median progression-free survival (PFS) of 4 months, median overall survival (OS) of 11 months, and the disease control rate (DCR) was 71.7%. The treatment effect can be predicted by the reduction of CA125 level after 2 courses. Patients with an increase and decrease in CA125 after 2 cycles of PLD, respectively, had a median OS of 14.5 (2-60) and 8 (2-51) months and a median PFS of 6 (2-38) months and 3 (0-47) months. CONCLUSION: PLD is clinically effective and useful because it provides a high DCR and is tolerable to adverse events. These findings can help support the use of PLD and guide physicians in their choice of treatment when encountering such cases.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).

  Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, Oishi T, Ihira K, Kato H, Goto M, Saito M, Taira Y, Yokoyama M, Shoji T, Kondo E, Mori A, Yokoi T, Iwasa-Inoue N, Hirashima Y, Nagasawa T, Takenaka M, Mikami M, Sugiyama T, Enomoto T

  Gynecologic oncology ( Gynecologic Oncology )  165 ( 3 ) 413 - 419   2022年06月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  OBJECTIVE: This multicenter, open-label, phase II study aimed to evaluate the efficacy and safety of paclitaxel-carboplatin, bevacizumab, and bevacizumab-based maintenance therapy for metastatic, recurrent, and persistent uterine cervical cancer. METHODS: Patients with measurable diseases that were not adapted to regional therapies, such as surgery or radiotherapy, and were systematic chemotherapy-naïve were eligible. The participants received paclitaxel (175 mg/m2), carboplatin (AUC 5), and bevacizumab (15 mg/m2) every three weeks until disease progression or unacceptable adverse events occurred. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall response rate (ORR), overall survival (OS), safety, and time to treatment failure. RESULTS: Sixty-nine patients were analyzed using our protocol. The median paclitaxel- carboplatin therapy duration was six cycles; 40% of patients received bevacizumab maintenance therapy. The median PFS was 11.3 months. The median OS was not reached; the median time to treatment failure was 5.9 months. The ORR was 79.7% [95% confidence interval (CI) 63.8-88.4]; 16 patients (23.2%) showed complete response (CR) and 39 patients (56.5%) showed partial response (PR). The median PFS was 14.3 months (95% CI 7.3-17 months) for the 25 patients who received maintenance therapy and 7.4 months (95% CI 6.1-11 months) for nonrecipients (p = 0.0449). Gastrointestinal perforation/fistulas occurred in four patients (5.6%), all of whom had a history of radiation therapy. CONCLUSIONS: Paclitaxel-carboplatin and bevacizumab therapy is an acceptable and tolerable treatment for advanced or recurrent cervical cancer.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program.

  Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, For The Mint Study Group

  Vaccines ( Vaccines )  10 ( 2 )   2022年01月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12-16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994-1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1-3 (CIN1-3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among "unvaccinated" cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012-2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0-10.0%, Ptrend = 0.03) and CIN2-3/AIS (62.5-36.4%, Ptrend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2-3/AIS diagnosed at age 20-24 years was lower in 1994-1999 birth cohorts compared with 1988-1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2-3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2-3/AIS suggests herd effects of HPV vaccination in Japan.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

全件表示 >>

MISC（その他業績・査読無し論文等） 【 表示 ／ 非表示 】

MISC（その他業績・査読無し論文等） 【 表示 ／ 非表示 】

• サルコペニアは子宮頸癌CCRT(concurrent chemoradiotherapy)症例での独立した予後因子である

  喜瀬 真雄, 新垣 精久, 高江洲 朋子, 渡部 俊陽, 柱本 真, 下地 裕子, 平良 祐介, 仲本 朋子, 久高 亘, 青木 陽一

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   233 - 233   2022年07月

   

• 当科で経験した直腸扁平上皮癌の3症例

  新垣 精久, 高江洲 朋子, 渡部 俊陽, 柱本 真, 下地 裕子, 平良 祐介, 仲本 朋子, 久高 亘, 青木 陽一

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   297 - 297   2022年07月

   

• 円錐切除術後に左踵に褥瘡を形成した一例

  高江洲 朋子, 久高 亘, 柱本 真, 渡部 俊陽, 下地 裕子, 新垣 精久, 平良 祐介, 仲本 朋子, 青木 陽一

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   293 - 293   2022年07月

   

• プラチナ不応性・抵抗性再発卵巣癌に対するリポソーマルドキソルビシンの効果とCA125値変動の解析

  大山 拓真, 下地 裕子, 仲宗根 忠栄, 新垣 精久, 平良 祐介, 仲本 朋子, 久高 亘, 青木 陽一

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   210 - 210   2022年07月

   

• 沖縄県における子宮頸癌のHPV型の変化

  下地 裕子, 渡部 俊陽, 柱本 真, 新垣 精久, 平良 祐介, 仲本 朋子, 久高 亘, 青木 陽一

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   225 - 225   2022年07月

   

全件表示 >>

SDGs 【 表示 ／ 非表示 】

SDGs 【 表示 ／ 非表示 】